CMA issues over £100m in fines after 1,110% thyroid drug price hike

The CMA has slapped more than £100 million worth of fines on Advanz Pharma, HgCapital and Cinven after it concluded that the price of a thyroid drug was inflated by 1,110%.

CMA_0.jpg
Advanz Pharma and Cinven told C+D they will appeal the CMA’s decision

The outcome of a Competition and Markets Authority’s (CMA) investigation, published today (July 29), found that Advanz charged an excessive price for its liothyronine tablets, which are used to treat thyroid hormone deficiency.

Free to registered users

Register to gain full access to C+D and C+D Community content

Sign in or register for free

Latest from News

Retired pharmacist crushed to death in canal boat accident

 
• By 
 • comment

Margaret Billings sustained fatal injuries when she was caught between a moving boat and a riverbank during a day out “with family and friends”, an inquest has found.

NHSE scrapped: ‘Fresh start or just more political chaos?’

 
• By 
 • comment

C+D rounds up some of the immediate pharmacy reaction to news that NHS England will be abolished, with more control moving back to the government and local leaders…

New primary care medical director role as 2-year NHSE axing begins

 
• By 
 • comment

Wes Streeting has revealed that the DH is “immediately” working to scrap NHS England (NHSE) and put a new “transformation team” in place – adding that it is in the “very final stages” of concluding a new pharmacy contract deal.

More from